Shreyass Joshi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shreyass joshi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shreyass Joshi Today - Breaking & Trending Today

Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer


Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer
Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years
May 25, 2021   Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose treatment integrated ....

United States , Emory University , Karenm Xu , Eduard Schreibmann , Davidm Schuster , Omer Kucuk , David Gauden , Josephw Shelton , Mehmeta Bilen , Asheshb Jani , Bradley Carthon , Olayinkaa Abiodun Ojo , Preteshr Patel , Mark Goodman , Sherrie Cooper , Bruce Hershatter , Peterj Rossi , Shreyass Joshi , Subir Goyal , Raghuveer Halkar , Winship Cancer Institute Of Emory University , Blue Earth Diagnostics , Winship Cancer Institute , Randomized Trial Comparing , Prostate Cancer , Emory Molecular Prostate Imaging ,

Blue Earth Diagnostics: The Lancet Publishes Results of Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer


(0)
- Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years -
- Winship Cancer Institute of Emory University s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 7 ....

United States , United Kingdom , Emory University , Karenm Xu , Eduard Schreibmann , Davidm Schuster , Omer Kucuk , David Gauden , Josephw Shelton , Asheshb Jani , Mehmeta Bilen , Bradley Carthon , Georgina Mowatt , Olayinkaa Abiodun Ojo , Priscilla Harlan , Preteshr Patel , Mark Goodman , Sherrie Cooper , Bruce Hershatter , Kostenloser Wertpapierhandel , Peterj Rossi , Shreyass Joshi , Subir Goyal , Mike Beyer , Raghuveer Halkar , Winship Cancer Institute Of Emory University ,

GSRGT 2020: Aggressive Surgical Approach for Nodal Disease


GSRGT 2020: Aggressive Surgical Approach for Nodal Disease
(UroToday.com) As part of the penile cancer session at the inaugural Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit, Dr. Maarten Albersen from Belgium discussed aggressive surgical approaches for managing patients with nodal disease. Dr. Albersen notes that risk of nodal metastasis is based on the European Association of Urology (EAU) risk delineation:
EAU good risk (pT1G1): 0% risk
EAU intermediate risk (pT1G2): 9% risk
EAU high risk (≥ pT2, G3, or LVI): 23% risk
Indeed, appropriate staging of the inguinal lymph nodes is crucial to management. Dynamic sentinel biopsy is one option but has a high false-negative rate outside of high-volume centers. The National Comprehensive Cancer Network (NCCN) guidelines suggest that 20 procedures performed annually should be the baseline, with a steep learning curve of ~30-50 cases. Comparatively, inguinal lymph node dissection has a low ....

Robertg Uzzo , Philippe Spiess , Davidy Chen , Rosalia Viterbo , Elizabeth Handorf , Maarten Albersen , Marcc Smaldone , Richarde Greenberg , Shreyass Joshi , Danielm Geynisman , Alexander Kutikov , Global Society Of Rare Genitourinary Tumors , National Cancer Database , European Association Of Urology , National Comprehensive Cancer Network , Global Society , Rare Genitourinary Tumors , European Association , Rare Genitourinary Tumors Virtual Summit , பிலிப் ஸ்பிஎஸ்ஸ் , ரோசாலியா வைட்டர்போ , எலிசபெத் ஹன்டோர்ப் , தேசிய புற்றுநோய் தரவுத்தளம் , ஐரோப்பிய சங்கம் ஆஃப் சிறுநீரகம் , தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் , உலகளாவிய சமூகம் ,